KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Resmed (RMD) Other Operating Expenses (2016 - 2025)

Resmed's Other Operating Expenses history spans 17 years, with the latest figure at $11.8 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 6.81% year-over-year to $11.8 million; the TTM value through Dec 2025 reached $46.6 million, up 3.78%, while the annual FY2023 figure was $20.2 million, N/A changed from the prior year.
  • Other Operating Expenses reached $11.8 million in Q4 2025 per RMD's latest filing, down from $12.0 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $18.0 million in Q4 2022 to a low of $7.4 million in Q1 2021.
  • Average Other Operating Expenses over 5 years is $10.7 million, with a median of $11.2 million recorded in 2024.
  • Peak YoY movement for Other Operating Expenses: soared 132.3% in 2022, then crashed 35.59% in 2023.
  • A 5-year view of Other Operating Expenses shows it stood at $7.7 million in 2021, then surged by 132.3% to $18.0 million in 2022, then plummeted by 35.59% to $11.6 million in 2023, then fell by 4.58% to $11.0 million in 2024, then grew by 6.81% to $11.8 million in 2025.
  • Per Business Quant, the three most recent readings for RMD's Other Operating Expenses are $11.8 million (Q4 2025), $12.0 million (Q3 2025), and $11.9 million (Q2 2025).